CVRX
BEARISH
$8.37
Live
CVRx, Inc. · NASDAQ
Target $11.17
(+33.4%)
$4.3
52W Range
$11.3
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 08, 2026
Market cap
$220.23M
P/E
N/A
ROE
-96.6%
Profit margin
-94.1%
Debt/Equity
1.28
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
75%
CVRX shows bearish fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Concerns include weak profitability or high valuation.
Key Strengths
Company has established market presence
Key Risks
Low profit margin of -94.1%
Weak ROE of -96.6%
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
36
Weak
50
50
30
50
0
AI Verdict
CVRX shows bearish fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Concerns include weak profitability or high valuation.
Key drivers: Company has established market presence, Low profit margin of -94.1%, Weak ROE of -96.6%
Confidence
35%
Value
50/100
Rule-based valuation (P/E + Graham).
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Future
50/100
Rule-based growth outlook.
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Past
30/100
Historical performance + price trend: Shares moved -70.1% over 5Y and -27.5% over 1Y.
Positives
- Insufficient data for clear positives.
Watchpoints
- ROE only -96.6%.
- Thin profit margins.
Health
50/100
Balance sheet & liquidity (Z-Score: N/A).
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Dividend
0/100
Dividend policy fallback.
Positives
- Insufficient data for clear positives.
Watchpoints
- No regular dividend payments.
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$8.37
Analyst Target
$11.17
Upside/Downside
+33.4%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for CVRX and closest competitors.
Updated 2026-04-07
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
CVRX
CVRx, Inc.
Primary
|
-70.1% | -7.4% | -27.5% | -4.1% | +6.5% | -11.5% |
|
ANIK
Anika Therapeutics, Inc.
Peer
|
-62.2% | -47.2% | -6.6% | +63.8% | +38.5% | +0.6% |
|
CAMP
CAMP4 THERAPEUTICS CORPORATION
Peer
|
-56.6% | -56.6% | +78.8% | +41.3% | -25.9% | +5.4% |
|
ALEC
Alector, Inc.
Peer
|
-88.2% | -66.9% | +53.9% | -20.0% | +14.6% | +10.0% |
|
ADAG
Adagene Inc.
Peer
|
-81.2% | +188.8% | +109.6% | +84.4% | +33.2% | +45.4% |
CVR
CVRx, Inc.
Primary
5Y
-70.1%
3Y
-7.4%
1Y
-27.5%
6M
-4.1%
1M
+6.5%
1W
-11.5%
ANI
Anika Therapeutics, Inc.
Peer
5Y
-62.2%
3Y
-47.2%
1Y
-6.6%
6M
+63.8%
1M
+38.5%
1W
+0.6%
CAM
CAMP4 THERAPEUTICS CORPORATION
Peer
5Y
-56.6%
3Y
-56.6%
1Y
+78.8%
6M
+41.3%
1M
-25.9%
1W
+5.4%
ALE
Alector, Inc.
Peer
5Y
-88.2%
3Y
-66.9%
1Y
+53.9%
6M
-20.0%
1M
+14.6%
1W
+10.0%
ADA
Adagene Inc.
Peer
5Y
-81.2%
3Y
+188.8%
1Y
+109.6%
6M
+84.4%
1M
+33.2%
1W
+45.4%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-4.71
PEG Ratio
N/A
P/B Ratio
5.6
P/S Ratio
3.89
EV/Revenue
3.44
EV/EBITDA
-3.86
Market Cap
$220.23M
Profitability
Profit margins and return metrics
Profit Margin
-94.09%
Operating Margin
-69.8%
Gross Margin
85.33%
ROE
-96.59%
ROA
-26.9%
Growth
Revenue and earnings growth rates
Revenue Growth
+4.4%
Earnings Growth
N/A
Q/Q Revenue Growth
+4.45%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
1.28
Moderate
Current Ratio
7.63
Strong
Quick Ratio
6.49
Excellent
Cash/Share
$2.88
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
86.3%
Op. Margin
-69.8%
Net Margin
-74.5%
Total Assets
$0.1B
Liabilities
$0.1B
Equity
$0.0B
Debt/Equity
1.66x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
101%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-14
$N/A
2026-02-12
$-0.46
-4.9% surprise
2025-11-05
$-0.49
+2.2% surprise
2025-08-04
$-0.57
-9.5% surprise
Healthcare Sector Comparison
Comparing CVRX against 174 companies in the Healthcare sector
(15 bullish, 57 neutral, 102 bearish)
Return on Equity (ROE)
-96.59%
This Stock
vs
-44.63%
Sector Avg
+116.4%
(Excellent)
Profit Margin
-94.09%
This Stock
vs
-21.27%
Sector Avg
+342.4%
(Superior)
Debt to Equity
1.28
This Stock
vs
5.38
Sector Avg
-76.1%
(Less Debt)
Revenue Growth
4.4%
This Stock
vs
114.69%
Sector Avg
-96.2%
(Slower)
Current Ratio
7.63
This Stock
vs
3.43
Sector Avg
+122.4%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
CVRX
CVRx, Inc.
|
BEARISH | $220.23M | - | -96.6% | -94.1% | $8.37 | |
|
ANIK
Anika Therapeutics, Inc.
|
BEARISH | $204.78M | - | -6.7% | -9.6% | $14.2 | Compare |
|
CAMP
CAMP4 THERAPEUTICS CORPORATION
|
BEARISH | $241.42M | - | -145.1% | -% | $4.65 | Compare |
|
ALEC
Alector, Inc.
|
BEARISH | $242.8M | - | -181.6% | -% | $2.2 | Compare |
|
ADAG
Adagene Inc.
|
BULLISH | $194.65M | - | -63.3% | -% | $4.13 | Compare |
CVRX
CVRx, Inc.
BEARISH
Mkt Cap
$220M
P/E
-
ROE
-96.6%
Price
$8.37
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-02 | MORRISON GREGORY | Officer | Stock Award | 34,000 | - |
| 2026-03-02 | HYKES KEVIN | Chief Executive Officer | Sale | 7,763 | $61,349 |
| 2026-03-02 | VERRASTRO PAUL | Officer | Sale | 1,284 | $10,146 |
| 2026-03-02 | OASHEIM JARED | Chief Financial Officer | Sale | 1,744 | $13,781 |
| 2026-03-02 | JOHN ROBERT ALLEN | Officer | Sale | 3,964 | $31,326 |
| 2026-03-02 | ADAMSON PHILIP B. | Officer | Sale | 1,262 | $9,973 |
| 2026-02-27 | HYKES KEVIN | Chief Executive Officer | Stock Award | 159,000 | - |
| 2026-02-27 | BINKOWSKI BRENT | Chief Operating Officer | Stock Award | 15,000 | - |
| 2026-02-27 | VERRASTRO PAUL | Officer | Stock Award | 45,000 | - |
| 2026-02-27 | OASHEIM JARED | Chief Financial Officer | Stock Award | 61,000 | - |
| 2026-02-27 | JOHN ROBERT ALLEN | Officer | Stock Award | 35,000 | - |
| 2026-02-27 | ADAMSON PHILIP B. | Officer | Stock Award | 41,000 | - |
| 2026-02-20 | JAIN MUDIT KUMAR | Director | Purchase | 46,800 | $297,592 |
| 2026-02-18 | JAIN MUDIT KUMAR | Director | Purchase | 600 | $2,785 |
| 2025-11-26 | JOHNSON & JOHNSON | Beneficial Owner of more than 10% of a Class of Security | Sale | 6,337 | $63,560 |
MORRISON GREGORY
Officer
2026-03-02
34,000 shares
HYKES KEVIN
Chief Executive Officer
2026-03-02
7,763 shares
·
$61,349
VERRASTRO PAUL
Officer
2026-03-02
1,284 shares
·
$10,146
OASHEIM JARED
Chief Financial Officer
2026-03-02
1,744 shares
·
$13,781
JOHN ROBERT ALLEN
Officer
2026-03-02
3,964 shares
·
$31,326
ADAMSON PHILIP B.
Officer
2026-03-02
1,262 shares
·
$9,973
HYKES KEVIN
Chief Executive Officer
2026-02-27
159,000 shares
BINKOWSKI BRENT
Chief Operating Officer
2026-02-27
15,000 shares
VERRASTRO PAUL
Officer
2026-02-27
45,000 shares
OASHEIM JARED
Chief Financial Officer
2026-02-27
61,000 shares
JOHN ROBERT ALLEN
Officer
2026-02-27
35,000 shares
ADAMSON PHILIP B.
Officer
2026-02-27
41,000 shares
JAIN MUDIT KUMAR
Director
2026-02-20
46,800 shares
·
$297,592
JAIN MUDIT KUMAR
Director
2026-02-18
600 shares
·
$2,785
JOHNSON & JOHNSON
Beneficial Owner of more than 10% of a Class of Security
2025-11-26
6,337 shares
·
$63,560
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
6 analysts
Canaccord Genuity
2026-02-13
Buy
Buy
Canaccord Genuity
2025-11-06
Buy
Buy
Cantor Fitzgerald
2025-11-06
Overweight
Overweight
Past News Coverage
Recent headlines mentioning CVRX from our newsroom.
Newest → oldest
No matching news yet.